Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
Expensive and softening.
Trading above fair value while the fundamentals weaken — little to like right now.
The five checks
1 caution · 4 warning
- WarningOvervaluedFair value ~$21 vs $29 — trading 26% above what the math supports.
- WarningPrice assumes a big accelerationYou'd need ~8%/yr free-cash-flow growth to justify today's price; it has done -29.6%/yr lately.
- WarningRevenue shrinkingDown 1.6% last year — cheap may mean broken.
- CautionCash flow flat-to-downFree cash flow ~-29.6%/yr — big, but not compounding. The crux for a value buyer.
- WarningHeavy debt loadNet debt of $51B — roughly 6× annual free cash flow. This changes the risk picture.
Price against fair value
What today's price assumes
Hold the price fixed and work backwards: how fast would free cash flow have to grow for $29 to make sense?
Price assumes a big acceleration.
How fair value is calculated
No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.
- Free cash flow, FY25Operating cash flow less capital spending, from the annual report$9B
- Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$74B
- Everything after year tenGrowing 2.5% a year, counted the same way+ $99B
- The business, in today's money$173B
- Subtract net debtBorrowings and finance leases less cash and securities− $51B
- Divide by the shares on file÷ 5.713B
Fair value per share$21
If our assumptions are wrong
Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $14 to $33 range comes from.
| 3% growth | 5% growth | 7% growth | |
|---|---|---|---|
| 8% discount | $22 | $27 | $33 |
| 9% discount | $17 | $21 | $26 |
| 10% discount | $14 | $17 | $21 |
The blue cell is the published method. Some cells sit above today’s price, some below.
Free cash flow, ten years
$ billions · Form 10-K
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
How this was built. Every figure is computed from Pfizer Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. We subtract net debt from the value of the business — for Pfizer that is about $51B, or $9 per share. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $28.89 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.
Read Pfizer another way
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →